Benaroya Resarch Institute (BRI) received a $5 million grant from the National Institutes of Health to find new treatments for peanut allergy through a collaboration involving three BRI labs, Virginia Mason physicians and sponsors of two clinical trials that are continents apart. An allergy to peanuts is one of the most common food allergies in the United States; more than 1.6 million children and teenagers have peanut allergy.
BRI Assistant Member Erik Wambre, PhD, and Virginia Mason physician, allergist and Principal Investigator David Jeong, MD, in Virginia Mason’s Clinical Research Center collaborated on a clinical trials program for a new oral medication that may prove a game-changer for children and adolescents who suffer peanut allergy.
The standard of care is a strict peanut-free diet and timely administration of rescue medications when allergic reactions occur. The aim is to reduce the frequency and severity of allergic reactions to peanuts and lower the risk for potentially life-threatening allergic reactions from accidental exposure to peanuts.
Food allergies are a large and growing problem, with millions suffering from life-threatening peanut allergy. While advances have been made, treatment options for people living with peanut allergy remain limited in their effectiveness and longevity.More Stories